GS 6779
Alternative Names: GS-6779; Hoopika HBV vaccine - Gilead SciencesLatest Information Update: 29 Mar 2024
At a glance
- Originator Hookipa Pharma
- Developer Gilead Sciences; Hookipa Pharma
- Class Hepatitis B vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Hepatitis B
Most Recent Events
- 03 Apr 2023 Phase-I clinical trials in Hepatitis B (Combination therapy, Prevention) in New Zealand (IM) (NCT05770895)
- 03 Apr 2023 Phase-I clinical trials in Hepatitis B (Monotherapy, Prevention) in New Zealand (IM) (NCT05770895)
- 21 Mar 2023 Gilead Sciences plans a phase Ia/Ib trial in chronic Hepatitis B (Combination therapy, Monotherapy, In volunteers), in March 2023 (IM) (NCT05770895)